Table 2 Treatment response in biochemical or imageological patients
From: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
Biochemical response (n, %) | Imageological response (n, %) | Overall response (n, %) | |
|---|---|---|---|
Complete response (CR) | 0 (0%) | 0 (0%) | 0 (0%) |
Partial response (PR) | 5 (26.32%) | 8 (36.36%) | 13 (31.71%) |
Stable disease (SD) | 12 (63.16%) | 7 (31.82%) | 19 (46.34%) |
Progressive disease (PD) | 2 (10.53%) | 7 (31.82%) | 9 (21.95%) |
Objective response rate (ORR) | 5 (26.32%) | 8 (36.36%) | 13 (31.71%) |
Disease control rate (DCR) | 17 (89.47%) | 15 (68.18%) | 32 (78.05%) |